Shanxi C&Y Pharmaceutical Group Co Ltd (300254) — Tangible Net Worth Ratio
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Tangible Net Worth Ratio of 61.0% as of March 2026. This metric is calculated by deducting intangible assets (CN¥200.46 Million) from net assets (CN¥514.07 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300254 book value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanxi C&Y Pharmaceutical Group Co Ltd Tangible Net Worth Ratio (2008–2025)
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Tangible Net Worth Ratio has changed across 18 annual periods from 2008 to 2025. As of March 2026, the ratio stands at 61.0%, reflecting net assets of CN¥514.07 Million with intangible assets of CN¥200.46 Million CNY. Also explore Shanxi C&Y Pharmaceutical Group Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Shanxi C&Y Pharmaceutical Group Co Ltd (300254) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.6% | CN¥594.33 Million | CN¥204.46 Million | CN¥1.64 Billion | ▲ +0.4 pp |
| 2024 | 65.2% | CN¥598.18 Million | CN¥208.11 Million | CN¥1.55 Billion | ▼ -8.0 pp |
| 2023 | 73.2% | CN¥778.43 Million | CN¥208.80 Million | CN¥1.43 Billion | ▲ +3.7 pp |
| 2022 | 69.5% | CN¥729.68 Million | CN¥222.63 Million | CN¥1.58 Billion | ▲ +1.1 pp |
| 2021 | 68.4% | CN¥744.58 Million | CN¥235.23 Million | CN¥1.53 Billion | ▼ -2.0 pp |
| 2020 | 70.4% | CN¥872.61 Million | CN¥258.38 Million | CN¥1.80 Billion | ▼ -16.7 pp |
| 2019 | 87.1% | CN¥932.60 Million | CN¥120.25 Million | CN¥1.80 Billion | ▲ +0.5 pp |
| 2018 | 86.6% | CN¥931.24 Million | CN¥124.46 Million | CN¥1.50 Billion | ▼ -0.1 pp |
| 2017 | 86.7% | CN¥971.17 Million | CN¥128.84 Million | CN¥1.52 Billion | ▲ +2.0 pp |
| 2016 | 84.8% | CN¥954.85 Million | CN¥145.40 Million | CN¥1.43 Billion | ▼ -4.6 pp |
| 2015 | 89.4% | CN¥872.50 Million | CN¥92.37 Million | CN¥1.31 Billion | ▲ +0.4 pp |
| 2014 | 89.1% | CN¥823.16 Million | CN¥90.07 Million | CN¥1.18 Billion | ▲ +2.5 pp |
| 2013 | 86.6% | CN¥767.16 Million | CN¥102.96 Million | CN¥1.09 Billion | ▲ +0.9 pp |
| 2012 | 85.7% | CN¥651.17 Million | CN¥93.25 Million | CN¥827.16 Million | ▼ -7.8 pp |
| 2011 | 93.5% | CN¥581.17 Million | CN¥37.65 Million | CN¥702.56 Million | ▲ +21.0 pp |
| 2010 | 72.6% | CN¥149.59 Million | CN¥41.05 Million | CN¥280.84 Million | ▼ -1.3 pp |
| 2009 | 73.9% | CN¥117.60 Million | CN¥30.69 Million | CN¥259.51 Million | ▼ -0.9 pp |
| 2008 | 74.8% | CN¥106.70 Million | CN¥26.88 Million | CN¥224.15 Million | — |